1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

SNOO Smart Sleeper Bassinet Wins FDA Clearance

 
• By Elizabeth Orr

The $1,700 infant sleeper is the first device to reach market indicated to help babies sleep on their backs. It was developed by Happiest Baby.

A family gathers around a dark-haired infant asleep in a SNOO bassinet.
• Source: PRNewsfoto/Happiest Baby, Inc.

Happiest Baby’s SNOO Smart Sleeper Bassinet has received de novo marketing authorization from the US Food and Drug Administration, making it the first device to reach market that is indicated to encourage safe sleep positioning in infants. The bassinet was cleared via the agency's breakthrough device program. 

SNOO uses a custom sleep sack that clips into the bassinet to ensure babies cannot roll from back to stomach or side. It is intended for infants aged up to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Policy & Regulation

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.